68Ga-PSMA-CYC PET imaging for diagnosing, staging, and restaging prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 1/2 interventional study gives men with confirmed prostate cancer a PET/CT scan with the novel tracer 68Ga-PSMA-CYC to record safety, whole-body biodistribution, and radiation dosimetry. Participants will also undergo head-to-head imaging comparisons with the established tracers 68Ga-PSMA-617 and 68Ga-PSMA-11 to compare lesion detection and image quality. The trial is prospective and conducted at a single site with informed consent required. Key outcomes include adverse events, organ radiation doses, and diagnostic performance versus the comparator tracers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* confirmed treated or untreated prostate cancer patients;
* signed written consent.

Exclusion Criteria:

* known allergy against PSMA;
* any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

Where it's running

• The First Affiliated Hospital of Fujian Medical University
  Fuzhou, Fujian, China Recruiting

Study contacts

• Principal investigator: Weibing Miao, MD — First Affiliated Hospital of Fujian Medical University
• Study coordinator: Weibing Miao, MD
• Email: miaoweibing@126.com
• Phone: 059187981618

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Normal PSA levels for trans women and non-binary people with prostates

  This study tests normal PSA reference levels in trans women and non-binary people who have prostates and are 40 or older.

  Recruiting Queen Mary University of London · London · NCT06987045

• Fezolinetant for hot flashes in men receiving androgen-deprivation therapy

  This test will try whether fezolinetant reduces hot flashes in men with prostate cancer who get them from androgen deprivation therapy.

  Recruiting Phase 2 University of Vermont · Burlington, Vermont · NCT06972875

• Ultralow-dose PET imaging for PSMA expression in prostate cancer

  This test will try to see if an ultralow-dose PET scan using 18F-DCFPyL can detect PSMA in people with and without prostate cancer while cutting radiation exposure by 10- to 100-fold.

  Recruiting Phase 2 Nuclear Imaging Institute · Englewood, New Jersey · NCT06904313

• Fasudil plus PD-1 antibody with androgen-deprivation therapy before prostatectomy.

  This trial tests whether adding fasudil and a PD-1 antibody to standard hormone (androgen-deprivation) therapy before prostatectomy helps men with locally advanced or oligometastatic prostate cancer.

  Recruiting Phase 2/3 Zhongda Hospital · Nanjing, Jiangsu · NCT06861192

• Two- versus five-fraction stereotactic ablative radiotherapy for intermediate-risk prostate cancer

  This trial tests whether giving prostate SABR in 2 treatments instead of 5 is as safe and effective for men with intermediate-risk prostate cancer.

  Recruiting at 2 sites Phase 2 British Columbia Cancer Agency · Surrey, British Columbia and 1 other locations · NCT06835725

• Neoadjuvant homoharringtonine with hormone therapy before prostatectomy

  This will test whether adding homoharringtonine to standard androgen-deprivation therapy before prostatectomy helps men with locally advanced or oligometastatic prostate cancer.

  Recruiting at 2 sites Phase 2 Zhongda Hospital · Nanjing, Jiangsu and 1 other locations · NCT06834321

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.